United States · Financial press · Investor's Business Daily
Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting
Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole. The post Why Biohaven Catapulted 30%-Plus —…
Read the full article on Investor's Business Daily Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)
